A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy

References

• GOLDGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [updated 2017] Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.htmlAccessed January 25, 2017
   Google Scholar
• BarrRGBourbeauJCamargoCARamFSInhaled tiotropium for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20052CD00287615846642
   PubMed Web of Science ®Google Scholar
• CheyneLIrvin-SellersMJWhiteJTiotropium versus ipratropium bromide for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20139CD009552
   Google Scholar
• KestenSCasaburiRKukafkaDCooperCBImprovement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patientsInt J Chron Obstruct Pulmon Dis20083112713618488436
   PubMedGoogle Scholar
• CalverleyPMAAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078
   PubMed Web of Science ®Google Scholar
• CelliBRMacNeeWATS/ERS Task ForceStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
   PubMed Web of Science ®Google Scholar
• WelteTMiravitllesMHernandezPEfficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2009180874175019644045
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLFergussonDTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
   PubMed Web of Science ®Google Scholar
• SilerTMKerwinESousaARDonaldAAliRChurchAEfficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studiesRespir Med201510991155116326117292
   PubMed Web of Science ®Google Scholar
• SilerTMKerwinESingletaryKBrooksJChurchAEfficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized, double-blind studiesCOPD201613111026451734
   PubMedGoogle Scholar
• TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human UseICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1)1996 Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdfAccessed March 16, 2017
   Google Scholar
• World Medical Association [webpage on the Internet]WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects2013 Available from: http://www.wma.net/en/30publications/10policies/b3/index.htmlAccessed March 16, 2017
   Google Scholar
• QuanHSundararajanVHalfonPCoding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative dataMed Care200543111130113916224307
   PubMed Web of Science ®Google Scholar
• BlaisLForgetARamachandranSRelative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherenceClin Ther20103271320132820678680
   PubMed Web of Science ®Google Scholar
• DalalAARobertsMHPetersenHVBlanchetteCMMapelDWComparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis201161322
   Web of Science ®Google Scholar
• RobertsMMapelDPetersenHBlanchetteCRamachandranSComparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD managementJ Med Econ201114676977621942463
   PubMedGoogle Scholar
• LokeYKSinghSRisk of acute urinary retention associated with inhaled anticholinergics in patients with chronic obstructive lung disease: systematic reviewTher Adv Drug Saf201341192625083248
   PubMedGoogle Scholar
• RobertsMHMapelDWBorregoMERaischDWGeorgopoulosLvan der GoesDSevere COPD exacerbation risk and long-acting bronchodilator treatments: comparison of three observational data analysis methodsDrugs Real World Outcomes20152216317527747765
   PubMedGoogle Scholar
• FabbriLMCalverleyPMIzquierdo-AlonsoJLRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLancet2009374969169570319716961
   PubMed Web of Science ®Google Scholar
• MartinezFJCalverleyPMGoehringUMBroseMFabbriLMRabeKFEffect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trialLancet2015385997185786625684586
   PubMed Web of Science ®Google Scholar
• CalzettaLRoglianiPMateraMGCazzolaMA systematic review with meta-analysis of dual Bronchodilation with LAMA/LABA for the treatment of stable COPDChest201614951181119626923629
   PubMed Web of Science ®Google Scholar
• CohenJSMilesMCDonohueJFOharJADual therapy strategies for COPD: the scientific rationale for LAMA + LABAInt J Chron Obstruct Pulmon Dis20161178579727143870
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWISDOM InvestigatorsWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar